A phase III multicentre randomised clinical trial comparing rituximab with CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin's lymphoma.

Trial Profile

A phase III multicentre randomised clinical trial comparing rituximab with CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin's lymphoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2015

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms R-CHOP 14 vs 21
  • Most Recent Events

    • 28 May 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 22 Apr 2013 Primary endpoint 'Overall-survival-rate' has not been met.
    • 22 Apr 2013 Results published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top